By tracking patent expirations, patent litigation, generic and biosimilar development, you can anticipate these market-shaping forces and stay one step ahead.
DrugPatentWatch Database Preview
Drugs in Development Information for AZD-1236
Email this page to a colleague
What is the drug development status for AZD-1236?
AZD-1236 is an investigational drug.
There have been 31 clinical trials for AZD-1236.
The most recent clinical trial was a Phase 2 trial, which was initiated on December 1st 2007.
The most common disease conditions in clinical trials are Small Cell Lung Carcinoma, Lung Neoplasms, and Adenocarcinoma. The leading clinical trial sponsors are AstraZeneca, Samsung Medical Center, and National Cancer Institute (NCI).
Summary for AZD-1236
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 13 |
| WIPO Patent Applications | 6 |
| Japanese Patent Applications | 5 |
| Clinical Trial Progress | Phase 2 (2007-12-01) |
| Vendors | 18 |
Recent Clinical Trials for AZD-1236
| Title | Sponsor | Phase |
|---|---|---|
| Durvalumab(MEDI4736) and AZD6738 Combination Therapy in Relapsed Small Cell Lung Cancer Subjects | AstraZeneca | Phase 2 |
| Durvalumab(MEDI4736) and AZD6738 Combination Therapy in Relapsed Small Cell Lung Cancer Subjects | Samsung Medical Center | Phase 2 |
| Adavosertib With or Without Olaparib in Treating Participants With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | National Cancer Institute (NCI) | Phase 2 |
Clinical Trial Summary for AZD-1236
Top disease conditions for AZD-1236
Top clinical trial sponsors for AZD-1236
US Patents for AZD-1236
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
